# Rezatapopt

Source: https://onco.cc/drugs/rezatapopt/  
OnCo record `rezatapopt` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rezatapopt is an experimental pill from PMV Pharma, in phase 2 trials for solid tumours with the TP53 Y220C mutation.

## Summary

Rezatapopt (PC14586) is a small molecule, oral from PMV Pharma. Binds the p53 protein made from the TP53 Y220C mutation, stabilising it so that it can work again as a tumour suppressor. It is being developed for any tumour type with the TP53 Y220C mutation, in the phase 2 part of the PYNNACLE study (NCT04585750); a study in myelodysplastic syndrome and acute myeloid leukaemia (NCT06616636) and a drug-interaction study (NCT07372625) are also recruiting. The company reports an FDA Fast Track designation.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Also known as: PC14586
- Tags: pipeline; ctgov-ingest
- Code: PC14586
- Modality: Small molecule, oral
- Mechanism: Binds the p53 protein made from the TP53 Y220C mutation, stabilising it so that it can work again as a tumour suppressor.

## Sources

- PMV Pharma pipeline: https://www.pmvpharma.com/pipeline/
- ClinicalTrials.gov NCT04585750: https://clinicaltrials.gov/study/NCT04585750
- ClinicalTrials.gov NCT07372625: https://clinicaltrials.gov/study/NCT07372625
- ClinicalTrials.gov NCT06616636: https://clinicaltrials.gov/study/NCT06616636

## Connected records

- targets: [TP53](https://onco.cc/targets/tp53/)
- companies: [PMV Pharma](https://onco.cc/companies/pmv-pharma/)
- trials: [A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)](https://onco.cc/trials/nct06616636/), [A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.](https://onco.cc/trials/nct07372625/), [The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)](https://onco.cc/trials/nct04585750/)

---
JSON: https://onco.cc/api/v1/entities/rezatapopt.json